SCHEMBL6670488

SCHEMBL6670488

Cc1cc(Br)cc(O)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.43
ALOX15 P16050 5/20 0.43
ALOX12 P18054 3/20 0.43
TRPA1 O75762 1/20 0.39
ATM Q13315 1/20 0.39
CYP3A4 P08684 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
TSHR P16473 1/20 0.38
HPGD P15428 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 1/20 0.36
PRNP P04156 1/20 0.36
HTT P42858 1/20 0.36
NOD2 Q9HC29 1/20 0.36
GABRA1 P14867 2/20 0.36
GABRB1 P18505 2/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30885796 1.00 ACHE (0.43) ACHEALOX15ALOX12TRPA1ATM
SCHEMBL9744264 0.86 ACHE (0.58) ACHEALOX15ALOX12TRPA1CYP3A4
SCHEMBL1755248 0.80 NQO2 (0.38) CYP3A4TDP1TSHRHPGDALDH1A1
SCHEMBL12189844 0.79 CYP3A4 (0.43) ALOX15ALOX12TRPA1CYP3A4TDP1
SCHEMBL11136759 0.79 CYP3A4 (0.50) ACHEALOX15ALOX12ATMCYP3A4
SCHEMBL18241199 0.75 ALOX15 (0.36) ALOX15ALOX12CYP3A4TDP1TSHR
SCHEMBL31089099 0.75 ALOX15 (0.36) ALOX15ALOX12CYP3A4TDP1TSHR
SCHEMBL27608122 0.75 CYP3A4 (0.48) ALOX15ALOX12CYP3A4TDP1TSHR
SCHEMBL1697593 0.75 ALDH1A1 (0.42) ALOX15ALOX12CYP3A4TDP1TSHR
SCHEMBL27642248 0.75 ALOX15 (0.36) ALOX15ALOX12CYP3A4TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010032461-A1 NITROGEN-CONTAINING FUSED RING COMPOUND 武田薬品工業株式会社 (JP) 2010-03-25 WO disclosed
EP-1227096-B1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE SATO PHARMA (JP) 2004-09-22 EP disclosed
US-6525066-B2 Bactericides; side effect reduction SATO PHARMACEUTICAL CO., LTD. (JP) 2003-02-25 US disclosed
US-20020173517-A1 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure SATO PHARMACEUTICAL CO., LTD. (JP) 2002-11-21 US disclosed
EP-1227096-A1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE Sato Pharmaceutical Co. Ltd. (JP) 2002-07-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173517-A1 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure IL4I1, TLR5, IFNG ACHE 4632/4885ALOX15 364/4885ALOX12 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.